Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Fig. 4

Erlotinib-resistant R#2 cells have increased integrin ligands binding compared to their parental erlotinib-sensitive, EGFR-mutant H3255 cells. H3255 (EGFR L585R) and its derived erlotinib-resistant R#2 cells were incubated with different integrin ligands (LXY30, LXW64, and LLP2A) for 2 h, 5 h, or overnight. The binding of tumor cells to integrin ligand-coated beads was visualized by light microscopy, and the intensity of binding was scored from negative (−), weakly, to strongly positive (1+ to 4+) (a). The binding of integrin ligands against tumor cells was confirmed by flow cytometry (b) and summarized in the table (c). h, hour(s); O/N, overnight; EGFR, epidermal growth factor receptor

Back to article page